For Immediate Release


Representative: Sunao Manabe, Representative Director, President and COO
(Code no.: 4568, First Section, Tokyo Stock Exchange)
Please address inquiries to Koji Ogawa, Corporate Officer,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126

Daiichi Sankyo Announces the Dissolution of Japan Vaccine

TOKYO, Japan (November 14, 2018) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that Daiichi Sankyo and GlaxoSmithKline K.K. (hereafter, GSK) have agreed to dissolve their joint venture company, Japan Vaccine Co., Ltd. (hereafter, Japan Vaccine).


Japan Vaccine was established in April 2012 as a joint venture between Daiichi Sankyo and GSK with the aim of contributing to the medical care though developing and selling prophylactic vaccines in Japan by combining the respective strengths of the two companies in the vaccines area. Since its establishment Japan Vaccine has achieved tangible results, enabling access to a variety of vaccines, especially for infants, and the market situation has improved over the last few years. However, in consideration of changes in the Japan Vaccine business situation, both parent companies believe they can better accomplish their mission to deliver vaccines to the Japanese market through separate operations. Daiichi Sankyo and GSK have therefore mutually agreed to dissolve Japan Vaccine, and will focus on building their respective vaccine businesses separately to further contribute to public health in Japan.


Daiichi Sankyo and GSK are committed to ensuring a sustainable supply of vaccines currently marketed by Japan Vaccine in Japan.


The timing of the dissolution and the transition of the business to the respective parent companies will be announced later once they have been decided.



Overview of Japan Vaccine

 (1) Trade name

Japan Vaccine Co., Ltd.

 (2) Headquarters

Tokyu Bancho Bldg., Yonbancho 6, Chiyoda-ku, Tokyo,  Japan

 (3) Name and title of Representatives

Hisaharu Hirai, Chairman & Co-CEO

Shinichi Terano, President & Co-CEO

 (4) Business description

Clinical development, marketing and sales of prophylactic vaccines in Japan

 (5) Capital

100 million yen

 (6) Ownership percentages

Daiichi Sankyo: 50%

GSK: 50%

 (7) Commencement of business

July 2, 2012

 (8) Number of Employees

About 270 (As of April, 2018)